-
Glaucoma neuroprotection moves into clinical trials
Friday, October 18, 2019Implant shows significant increase in nerve fibre layer thickness
-
Phaco over trab or shunt for PACG
Tuesday, October 1, 2019Cataract extraction may be better first surgical option than trab or tube
-
Slowing glaucoma progression
Tuesday, October 1, 2019Blocking connexins in retinal astrocytes may help protect the optic nerve
-
Detecting early glaucoma
Wednesday, September 25, 2019Considerations needed for building certainty when diagnosing glaucoma
-
Characterising progression key for glaucoma management
Saturday, September 14, 2019Best tools seem inadequate to detect slower rates of progression
-
Novel device addresses limitations of gonioscopy
Saturday, September 14, 2019Automated gonioscopy has many advantages and exciting potential
-
Diagnosis based on optic disc evaluation involves care
Saturday, September 14, 2019How to recognise typical optic disc features in early disease
-
Combination therapy
Sunday, September 1, 2019Intravitreal dexamethasone combined with systemic immunosuppressive therapy is an effective approach to the treatment of uveitis
-
Aerie in Europe
Sunday, September 1, 2019Aerie’s recently completed state-of-the-art sterile fill facility in Athlone, Ireland With US Food and Drug Administration approval of its first product in December 2017, newcomer Aerie Pharmaceuticals made history. The company’s proprietary Rho kinase (ROCK) inhibitor eye drop, Rhopressa (netarsudil ophthalmic solution) 0.02%, represented the first new drug class approved in the US for reducing […]
-
Advances in glaucoma
Sunday, September 1, 2019New glaucoma medications may extend the range of medical IOP control,
